secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001628280-24-036859
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics cuts workforce 43%, suspends OV329 IV, reports Q2 net income of $8.5M on $77M cash
--------------------------------------------------------------------------------

- Reduced headcount by 17 employees (43%) to prioritize core programs; expects $3.4M cash restructuring costs through mid-2025.
- Suspended OV329 IV program for refractory status epilepticus; oral OV329 Phase 1 MAD results due H2 2024.
- Appointed Dr. Amanda Banks as Chief Development Officer in July 2024.
- Q2 2024 net income of $8.5M ($0.12 EPS) vs net loss of $12.4M ($0.18 loss) in 2023, aided by $29M fair value gain on royalty liability.
- Cash and marketable securities of $77.0M expected to fund operations and 5 clinical/regulatory milestones through late H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828024036859/0001628280-24-036859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828024036859/ovid-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-036859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer